What Researchers Did
Two mathematical modelers developed a computational model of diabetic wound healing to predict which patients would benefit from HBOT alone versus HBOT combined with quercetin, a senolytic drug that clears aging, dysfunctional cells.
What They Found
The model predicted that HBOT alone achieves wound closure within normal timeframes for a limited subset of biologically older patients. When quercetin was added to HBOT, this subset expanded significantly, suggesting the combination could help patients who would not respond to HBOT alone. The benefits depended on two biological aging parameters linked to fibroblast activity and VEGF protein production.
What This Means for Canadian Patients
For older Canadians with diabetic wounds that fail to heal despite HBOT, this model suggests that adding a senolytic drug like quercetin, which targets the aging cells that impair wound repair, may make HBOT effective for a broader group. This is a theoretical finding requiring clinical validation.
Canadian Relevance
Diabetic foot ulcers are an OHIP-covered indication for HBOT in Ontario, making this research directly relevant to the Canadian clinical context.
Study Limitations
This is a mathematical model, not a clinical study; the aging parameters used have not yet been linked to measurable clinical biomarkers, so results cannot yet be applied to individual patients.